DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS UNDER ANTI-FIBROTIC TREATMENT

被引：0
|
作者：
Cilli, Aykut [1 ]
Uzer, Fatih [1 ]
机构：
[1] Akdeniz Univ, Dept Resp Dis, Antalya, Turkiye
来源：
SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES | 2023年 / 40卷 / 03期
关键词：
IPF; disease progression; nintedanib; pirfenidone; BRONCHOALVEOLAR LAVAGE; LUNG-FUNCTION; PIRFENIDONE; NINTEDANIB; EFFICACY; EXPERIENCE; SAFETY;
D O I：
10.36141/svdld.v40i3.14048
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Idiopathic pulmonary fibrosis (IPF) is the most common progressive interstitial disease of unknown etiology. The course of the disease cannot be predicted with certainty. It is crucial to regularly monitor the disease using multiple assessments to evaluate its progression. Currently, there is no consensus on the exact definition of disease progression. Although nintedanib and pirfenidone can slow down the progression of IPF, the disease can still advance even under anti-fibrotic treatment. The aim of this review is to examine and summarize the current data regarding IPF progression in patients receiving anti-fibrotic treatment, while also highlighting the limitations of the tests used for assessing disease progression
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] A review of Idiopathic Pulmonary Fibrosis patients on anti-fibrotic treatment in the mid west area
    Ryan, N.
    Ryan, P.
    Gleeson, E.
    Cullinan, M.
    Mcinerney, C.
    Casserly, B.
    O'Brien, A.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S441 - S442
  • [3] The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
    Matsumoto, Yoko
    Furukawa, Ryutaro
    Ohara, Sayaka
    Usui, Kazuhiro
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [4] Anti-Fibrotic Therapy and Patient Reported Outcomes in Idiopathic Pulmonary Fibrosis
    Kay, S.
    White, E. S.
    Sheth, J. S.
    Flaherty, C.
    Getty, C.
    Holtze, C.
    Wang, B.
    Salisbury, M.
    Belloli, E.
    Flaherty, K. R.
    Murray, S.
    Xia, M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [5] Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
    Nair, Girish B.
    Matela, Ajsza
    Kurbanov, Daniel
    Raghu, Ganesh
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) : 699 - 711
  • [6] Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis
    Hasaneen, Nadia
    Tuong Vu
    Fusiak, Timothy
    Foda, Hussein
    Condos, Rany
    Smaldone, Gerald
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [7] Factors Affecting The Selection Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Ahmad, S.
    Shlobin, O. A.
    Weir, N.
    Nathan, S. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [8] A HUMAN MODEL OF LUNG FIBROSIS FOR THE ASSESSMENT OF ANTI-FIBROTIC STRATEGIES IN IDIOPATHIC PULMONARY FIBROSIS
    Roach, K. M.
    Tongue, P.
    Castells, E.
    Elliot, G.
    Marshall, H.
    Richardson, M.
    Mason, S.
    Chachi, L.
    Bradding, P.
    [J]. THORAX, 2019, 74 : A56 - A57
  • [9] Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis
    Sugino, Keishi
    Ono, Hirotaka
    Saito, Mikako
    Ando, Masahiro
    Tsuboi, Eiyasu
    [J]. PLOS ONE, 2024, 19 (06):
  • [10] Real-life survival of idiopathic pulmonary fibrosis with anti-fibrotic medication
    Bleinc, Alexandre
    Blin, Timothee
    Legue, Sylvie
    Mankikian, Julie
    Plantier, Laurent
    Marchand-Adam, Sylvain
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (05) : 371 - 381
12345